Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and triage patients with suspected hypertrophic cardiomyopathy (HCM). The Viz HCM provider workflow software automatically reviews routine electrocardiograms (ECGs), detects cases of suspected HCM and alerts the cardiologist who performed the ECG. It is hoped that this will help physicians to diagnose HCM faster and in a more efficient way. Viz.ai has filed a de novo request to the FDA for the software as a Software-as-a-Medical-Device (SaMD), which has been accepted for review. It provides a mobile-based ECG viewer with AI alerts and communication tools, all aiming to improve cardiac care communication.